News | Mammography | June 14, 2019

Fujifilm Announces Nationwide Breast Health Campaign With Mobile Mammography Coach

Eighteen-month, 48-state campaign looks to improve access to breast health education and mammography screening services

Fujifilm Announces Nationwide Breast Health Campaign With Mobile Mammography Coach

At the center of the campaign, Fujifilm will be traveling around the U.S. with its "Aspire to Be Fearless" mobile mammography coach to provide educational opportunities for clinicians, raise awareness about the importance of screening and will be providing mammograms to the underserved population in key locations.

June 14, 2019 — Fujifilm Medical Systems U.S.A. Inc. announced a nationwide awareness campaign titled ‘Aspire to Be Fearless’ focused on improving access to breast health education and mammography screening services for every woman that needs it, especially those most reluctant. At the center of the campaign, Fujifilm will be traveling around the U.S. with its ‘Aspire to Be Fearless’ mobile mammography coach to provide educational opportunities for clinicians, raise awareness about the importance of screening and will be providing mammograms to the underserved population in key locations.

Fujifilm kicked-off the campaign by supporting an educational event, the Pink Table Brunch, on June 12, 2019 in Portland, Ore. The event featured experts in the field of health, nutrition and breast care. Each presenter shared the latest information about what participants need to know in order to help lessen the fear if they or a loved one is diagnosed with breast cancer. Nisha Jackson, Ph.D., author of a new book entitled “Brilliant Burnout,” signed her latest book at the event.

According to Fujifilm, breast cancer is one of the most feared cancers among women and some women may feel so apprehensive that they put off their breast exams.1 National Cancer Institute statistics show 1 in 8 women may be diagnosed with breast cancer at some time during her life2. Finding breast cancer early and getting state-of-the-art cancer treatment are the most important strategies to prevent deaths from breast cancer.3  Women whose breast cancer is detected at an early stage have on average a 90 percent survival rate in the first five years.4 Unfortunately, minority women are more likely to be diagnosed at a later stage of breast cancer, in part due to barriers to timely screening mammography, resulting in poorer mortality and survival outcomes.5

The ‘Aspire to Be Fearless’ mobile mammography coach will be equipped with a waiting room, dressing room, Aspire Cristalle digital mammography system with digital breast tomosynthesis and Aspire Bellus II mammography diagnostic workstation. Mammography screening services will be available beginning fall 2019. A series of educational events will be hosted by Fujifilm throughout the year in select markets around the country, reaching 48 states over the course of 18 months.

For more information please visit www.fujimed.com

 

References

1.  “Overcoming the Fear of Breast Cancer.” HealthyWomen.Org. Retrieved from https://www.healthywomen.org/content/article/overcoming-fear-breast-cancer

2. “Breast Cancer Risk in American Women.” National Cancer Institute. Retrieved from https://www.cancer.gov/types/breast/risk-fact-sheet

3. “American Cancer Society Recommendations for the Early Detection of Breast Cancer.” American Cancer Society. Retrieved from https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html

4. “Survival Rates for Breast Cancer.”  American Cancer Society.” Retrieved from https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html

5. “Gendered and Racialized Social Expectations, Barriers, and Delayed Breast Cancer Diagnosis” Cancer Journal (September 24, 2018).  Retrieved from https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.31636?purchase_referrer=www.breastcancer.org&tracking_action=preview_click&r3_referer=wol&show_checkout=1

Related Content

FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients
Technology | Contrast Media | July 15, 2019
The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance...
Graphic courtesy Pixabay

Graphic courtesy Pixabay

Feature | Artificial Intelligence | July 15, 2019 | By Greg Freiherr
Siemens has long focused on automation as a way to make diagnostic equipment faster and more efficient.
Videos | Artificial Intelligence | July 12, 2019
Khan Siddiqui, M.D., founder and CEO of HOPPR, discusses the economic advantages and costs presented by...
Routine scan of abdomen pelvis taken with the UW-Madison’s Revolution 256 CT scanner using the FDA-cleared reconstruction algorithm, called TrueFidelity.

Routine scan of abdomen pelvis taken with the UW-Madison’s Revolution 256 CT scanner using the FDA-cleared reconstruction algorithm, called TrueFidelity. UW-Madison was the first site in the U.S. to get this technology. Its use is now being integrated into UW CT protocols. Image courtesy of Timothy P. Szczykutowicz

Feature | Computed Tomography (CT) | July 12, 2019 | By Greg Freiherr
When providers develop their own imaging protocols, they are wasting time and money, according to...
Videos | Digital Pathology | July 11, 2019
Toby Cornish, M.D., Ph.D., associate professor and medical director of informatics at the University of Colorado Scho
Fluke Biomedical Introduces RaySafe 452 Survey Meter
Technology | Radiation Dose Management | July 11, 2019
Radiation measurement often requires different devices for varying applications, adding to the cost and complexity of...
FDA Clears Koios DS Breast 2.0 AI-based Software
News | Ultrasound Women's Health | July 11, 2019
Koios Medical announced its second 510(k) clearance from the U.S. Food and Drug Administration (FDA).
SimonMed Imaging Implements ProFound AI for 3-D Tomosynthesis
News | Mammography | July 10, 2019
Arizona-based SimonMed Imaging announced their implementation of the first U.S. Food and Drug Administration (FDA)-...
IBA Launches Monte Carlo Patient QA for Varian Halcyon at AAPM 2019
Technology | Quality Assurance (QA) | July 10, 2019
IBA announced the launch of the latest functionality of the SciMoCa Monte Carlo Patient QA solution at the 61st annual...
Researchers Use Artificial Intelligence to Deliver Personalized Radiation Therapy
News | Radiation Therapy | July 09, 2019
New Cleveland Clinic-led research shows that artificial intelligence (AI) can use medical scans and health records to...